Cooperation for Primary Care Patients on Sick Leave for CMD: Care Manager and Workplace Intervention - CO-WORK-CARE

Sponsor
Göteborg University (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT03250026
Collaborator
Vastra Gotaland Region (Other)
349
1
2
72.8
4.8

Study Details

Study Description

Brief Summary

This study aims to evaluate whether a convergence dialogue during sick leave, between the employee and the employer, with the Primary Care Centre Rehab Coordinator as discussion leader, leads to reduced sick leave time compared to those individuals who only have contact with a Care Manager during the period of sick leave. The study will be performed as a randomised controlled trial with randomisation at the PCC level where intervention PCCs offers a convergence dialogue meeting with the work place representative during sick leave in addition to Care Manager contact.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Workplace convergence dialogue
  • Behavioral: Care Manager
N/A

Detailed Description

In Sweden sick leave time and frequency are increasing. This is primarily in the area of common mental disorders (CMD), and CMD is now the most common single cause of sickness absence. Primary care is the area in which most individuals with mental illness seek care and also receive care. A Care Manager function at the primary care centre (PCC) where the Care Manager is responsible for the support and close contact with patients with CMD and act as the "spider in the web" and combine patient support with other measures, have been shown to have beneficial effects for depression course. In Region Västra Götaland an implementation of the Care Manager function at the PCC has been set out, and the function is now available in nearly 100 PCCs in the region. The present study aims to evaluate whether a convergence dialogue during sick leave, between the employee and the employer, with the PCCs Rehab Coordinator as discussion leader, leads to reduced sick leave time compared to those individuals who only have contact with the Care Manager during the period of sick leave. The study will be performed as pragmatic randomised controlled trial with randomisation at the PCC level. Around 20 PCCs with a Care Manager function for patients on sick-leave with CMD diagnosis will be recruited and randomized to intervention where patients in addition to a Care Manager contact (12 weeks) will have one convergence dialogue meeting with the work place representative during sick leave. Control PCCs will give Care Manager contact 12 weeks only.

Study Design

Study Type:
Interventional
Actual Enrollment :
349 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Pragmatic randomised controlled trial; randomisation on primary care centre levelPragmatic randomised controlled trial; randomisation on primary care centre level
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Cooperation for Patients With Common Mental Disorders: Care Manager Function at the Primary Care Centre and Intervention at the Workplace - CO-WORK-CARE
Actual Study Start Date :
Dec 5, 2017
Anticipated Primary Completion Date :
Dec 31, 2023
Anticipated Study Completion Date :
Dec 31, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Intervention (Workplace dialogue)

Intervention: Work place convergence dialogue contact

Behavioral: Workplace convergence dialogue
Work place contact as a convergence dialogue between the employer and employee with the Rehab Coordinator as a guide

Behavioral: Care Manager
Regular contact Care Manager during around 12 weeks

Active Comparator: Care Manager

Intervention: Care Manager contact 12 weeks (Care as usual)

Behavioral: Care Manager
Regular contact Care Manager during around 12 weeks

Outcome Measures

Primary Outcome Measures

  1. Net and gross sick-leave days [12 months]

    number of net and gross sick-leave days during 12 months

Secondary Outcome Measures

  1. Depressive symptoms [6 and 12 months]

    Change of depressive symptoms Montgomery-Asberg Depression Rating Scale - Self rating version (MADRS-S) Range 0-60 (Total score) Low score better outcome

  2. Anxiety symptoms [6 and 12 months]

    Change of anxiety symptoms Generalized Anxiety Disorder 7-item (GAD-7) scale Range 0-15 (total score) low score better outcome

  3. Quality-of-life questionnaire score [6 and 12 months]

    Change of quality of life EuroQoL-5 Dimension Questionnaire(EQ-5D) Range 0-1.0(total score) low score worst outcome

  4. Work ability [6 and 12 months]

    Change of work ability Work Ability Index (WAI) Range 7-49 (total score) low score worst outcome

  5. Exhaustion [6 and 12 months]

    Change of Exhaustion Karolinska Exhaustion Disorder Scale (KEDS) Range 0-54 (total score) low score better outcome

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 67 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:

Patients attending primary care centers with care manager function

  • aged >=18 to 67 years

  • diagnosed with a new (< 1 month) depression diagnose (F32, F33), anxiety syndrome (F41, F48) or stress related adjustment disorder (F43)

  • on sick-leave > 14 days

Exclusion Criteria:
  • Bipolar disorder

  • psychosis

  • addiction

  • other serious mental disorder

  • suicidal ideation or earlier suicide attempt

  • cognitive impairment or not speaking/understanding Swedish

Contacts and Locations

Locations

Site City State Country Postal Code
1 Department of Primary Health Care, Sahlgrenska Academy Göteborg Region Västra Götaland Sweden 40530

Sponsors and Collaborators

  • Göteborg University
  • Vastra Gotaland Region

Investigators

  • Principal Investigator: Cecilia Björkelund, prof, Göteborg University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Göteborg University
ClinicalTrials.gov Identifier:
NCT03250026
Other Study ID Numbers:
  • 459-17
First Posted:
Aug 15, 2017
Last Update Posted:
Aug 16, 2022
Last Verified:
Mar 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Göteborg University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 16, 2022